<DOC>
	<DOCNO>NCT00451191</DOCNO>
	<brief_summary>This double-blind randomized phase II trial determine whether two different dos BoNT/A injection prostate gland demonstrate sufficient improvement management low urinary symptom due BPH warrant extensive research . Subjects receive either 100U 300U dose . Participation last 1 year .</brief_summary>
	<brief_title>Botulinum Toxin Injection Management BPH</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Male least 50 year age . Voided volume = &gt; 125 ml . Maximum urinary flow &lt; 15 ml/sec . AUA symptom severity score = &gt; 8 . Patient sign informed consent prior performance study procedure . Patient able complete study protocol opinion investigator . Any prior surgical intervention BPH . Current diagnosis acute chronic prostatitis ( may cause LUTS mimic BPH ) . Overactive bladder without bladder outlet obstruction . Enrolled another treatment trial disease within past 30 day . Men interested future fertility . Previous exposure botulinum toxin . On alphablocker within past 48 hour . On 5alphareductase inhibitor within past month . Post void residual &gt; 350 ml . On phenylephrine , pseudoephedrine , imipramine , anticholinergic , cholinergic medication within past 2 week . On estrogen , androgen , drug produce androgen suppression , anabolic steroid within past 4 month . Clinically significant renal hepatic impairment determine abnormal creatinine AST level ( base local institutional value ) . Serum prostate specific antigen level &gt; 8 ng/ml ( Hybritech ) . For PSA 48 ng/ml , PSA elevation must consider benign cause opinion PI . This decision base PSA velocity , previous TRUS biopsy , percent free PSA , clinical estimation keep sound urologic care . Active urinary tract disease biopsy prostate within past 6 week . Daily use pad device incontinence require . Episode unstable angina pectoris , myocardial infarction , transient ischemic attack , cerebrovascular accident ( stroke ) within past 6 month . On aminoglycosides drug interfere neuromuscular transmission . EatonLambert syndrome , hemophilia , hereditary clotting factor deficiency , bleed diathesis . Penile prosthesis artificial urinary sphincter . History current evidence carcinoma prostate bladder , pelvic radiation surgery , urethral stricture , bladder neck obstruction . Known primary neurologic condition multiple sclerosis , myasthenia gravis Parkinson 's disease , neurological disease know affect bladder function . Documented bacterial acute prostatitis within past year . Two document urinary tract infection type past year ( UTI define &gt; 100,000 colony per ml urine midstream clean catch catheterize specimen ) . History bladder calculus . Patients must aspirin , NSAIDS , Coumadin 7 day prior botulinum toxin injection . Cancer consider cure , except basal cell squamous cell carcinoma skin ( cure define evidence cancer within past 5 year ) . Any serious medical condition likely impede successful completion study , certain mental disorder , hypersensitivity botulinum toxin anesthetic use study , syncope , uncontrolled diabetes .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>botulinum toxin</keyword>
	<keyword>BoNT/A</keyword>
</DOC>